Stock Update (NYSE:BSX): Boston Scientific Receives U.S. FDA Approval For ImageReady™ MR-Conditional Pacing System

[PR Newswire] – MARLBOROUGH, Mass., April 25, 2016 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for use in a magnetic … Read more on this. Boston Scientific Corporation (BSX) , with a current market cap of $26.73B, opened at $19.72. During the trading session, BSX traded between $19.66 to $19.84 with its 52-week range being $14.18 to $19.84. BSX shares are currently priced at 18.66x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 6.39x earnings multiple for the same period. Consensus earnings for the current quarter by the 25 sell-side analysts covering the stock is an estimate of $0.24 per share, which would be $0.03 better than the year-ago quarter and a $0.00 sequential decrease. Investors should also note that the full-year EPS estimate of $1.05 is a $0.12 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $1.91 Billion. If reported, that would be a 7.91% increase over the year-ago quarter. Recently, Nomura Initiated BSX at Buy (Mar 17, 2016). Previously, Sun Trust Rbsn Humphrey Initiated BSX at to Buy. The average price target for BSX shares by the analysts covering it is $21.32, which is 8.11% above where the stock opened. See more in (NYSE:BSX) Similar Articles: Market Update: Boston Scientific Corporation (NYSE:BSX) – Boston Scientific to Participate in Barclays Global Health Care Conference Market Update: Boston Scientific Corporation (NYSE:BSX) – Boston Scientific Receives U.S. FDA Approval For Quadripolar Leads And Initiates Global Trial To Expand MRI Labeling To The U.S. And Asia Company Update: Boston Scientific Corporation (NYSE:BSX) – Boston Scientific to Participate in Leerink Partners 2016 Healthcare Conference